---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029401"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:14:06.292702+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liquidia's YUTREPIA NDA resubmission accepted; PDUFA date May 24, 2025

## Summary
- FDA accepted Liquidia's NDA resubmission for YUTREPIA (treprostinil) inhalation powder.
- Resubmission is a complete, Class 1 response to the August 16, 2024 action letter.
- FDA granted tentative approval for PAH and PH-ILD; final approval decision by May 24, 2025.
- Company preparing for launch of YUTREPIA pending final FDA approval.

## SEC filing metadata
- accession: 0001104659-25-029401
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/0001104659-25-029401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/tm2510788-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029401
- JSON: https://secwatch.observer/filing/0001104659-25-029401.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.